The Homelessness and TB Toolkit is an online resource developed to assist both public health programs and homeless service agencies in the important work of TB control among people experiencing homelessness. The toolkit contains guidelines, forms, signs, educational materials, articles, and other resources. Many of the tools found on the site are presented as templates that can be modified or edited for a given program’s needs.
This series of patient education fact sheets provides information on drugs used in the treatment of TB (e.g., Clofazimine, Ethambutol, Ethionamide, Isoniazid, Levofloxacin, Moxifloxacin, PASER [p-aminosalicylic acid granules], Pyrazinamide, Pyridoxine, Rifabutin, Rifampin, Streptomycin). The fact sheets include information on medication side effects, actions to take if side effects occur, and instructions in the event a dose of medication is missed.
This series of patient education fact sheets provides information on drugs used in the treatment of TB (e.g., Clofazimine, Ethambutol, Ethionamide, Isoniazid, Levofloxacin, Moxifloxacin, PASER [p-aminosalicylic acid granules], Pyrazinamide, Pyridoxine, Rifabutin, Rifampin, Streptomycin). The fact sheets include information on medication side effects, actions to take if side effects occur, and instructions in the event a dose of medication is missed.
This series of patient education fact sheets provides information on drugs used in the treatment of TB (e.g., Clofazimine, Ethambutol, Ethionamide, Isoniazid, Levofloxacin, Moxifloxacin, PASER [p-aminosalicylic acid granules], Pyrazinamide, Pyridoxine, Rifabutin, Rifampin, Streptomycin). The fact sheets include information on medication side effects, actions to take if side effects occur, and instructions in the event a dose of medication is missed.
This document provides general guidance and examples on implementing contact investigations in low- and middle-income settings. The World Health Organization (WHO) policy document "Recommendations for Investigating Contacts of Persons with Infectious Tuberculosis in Low- and Middle-Income Countries", published in late 2012, presents definitions and recommendations for what should be done for contact investigation; this document presents suggestions and examples of how the recommendations can be put into operation.
This infographic uses an iceberg to demonstrate how many people have latent TB infection and TB disease.
This series of patient education fact sheets provides information on drugs used in the treatment of TB (e.g., Clofazimine, Ethambutol, Ethionamide, Isoniazid, Levofloxacin, Moxifloxacin, PASER [p-aminosalicylic acid granules], Pyrazinamide, Pyridoxine, Rifabutin, Rifampin, Streptomycin). The fact sheets include information on medication side effects, actions to take if side effects occur, and instructions in the event a dose of medication is missed.
This document presents guidance on the design and implementation of surveys and surveillance systems to measure the burden and trends of drug-resistant tuberculosis.
This infographic depicts the global epidemiology of TB.
This series of patient education fact sheets provides information on drugs used in the treatment of TB (e.g., Clofazimine, Ethambutol, Ethionamide, Isoniazid, Levofloxacin, Moxifloxacin, PASER [p-aminosalicylic acid granules], Pyrazinamide, Pyridoxine, Rifabutin, Rifampin, Streptomycin). The fact sheets include information on medication side effects, actions to take if side effects occur, and instructions in the event a dose of medication is missed.
